Furthermore, miR-192 directly targets Bcl-2, thereby influencing apoptosis and resistance of A549 cells in response to cisplatin and gemcitabine, a therapy combination frequently used for NSCLC [29]. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.